BookR: School of Health Core Facilities Booking
PubMed Publications| Keyword search (4,163 papers available) |  |
"Liao M" Authored Publications:
| Title | Authors | PubMed ID | |
|---|---|---|---|
| 1 | A Spike-Accum bioconjugate protein vaccine confers potent SARS-CoV-2-specific immunity | Pierre Bikorimana J; Caveney NA; El-Hachem N; Mandl GA; Capobianco JA; Stanga D; Abusarah J; Hancock MA; Farah R; Gonçalves MP; Falzarano D; Liao M; Hamonic G; Liu Q; Beaudoin S; Talbot S; Rafei M; | 41054531 CNSR |
| 2 | Probability of major depression diagnostic classification based on the SCID, CIDI and MINI diagnostic interviews controlling for Hospital Anxiety and Depression Scale - Depression subscale scores: An individual participant data meta-analysis of 73 primary studies | Wu Y; Levis B; Sun Y; Krishnan A; He C; Riehm KE; Rice DB; Azar M; Yan XW; Neupane D; Bhandari PM; Imran M; Chiovitti MJ; Saadat N; Boruff JT; Cuijpers P; Gilbody S; McMillan D; Ioannidis JPA; Kloda LA; Patten SB; Shrier I; Ziegelstein RC; Henry M; Ismail Z; Loiselle CG; Mitchell ND; Tonelli M; Al-Adawi S; Beraldi A; Braeken APBM; Büel-Drabe N; Bunevicius A; Carter G; Chen CK; Cheung G; Clover K; Conroy RM; Cukor D; da Rocha E Silva CE; Dabscheck E; Daray FM; Douven E; Downing MG; Feinstein A; Ferentinos PP; Fischer FH; Flint AJ; Fujimori M; Gallagher P; Gandy M; Goebel S; Grassi L; Härter M; Jenewein J; Jetté N; Julião M; Kim JM; Kim SW; Kjærgaard M; Köhler S; Loosman WL; Löwe B; Martin-Santos R; Massardo L; Matsuoka Y; Mehnert A; Michopoulos I; Misery L; Navines R; O' Donnell ML; Öztürk A; Peceliuniene J; Pintor L; Ponsford JL; Quinn TJ; Reme SE; Reuter K; Rooney AG; Sánchez-González R; Schwarzbold ML; Senturk Cankorur V; Shaaban J; Sharpe L; Sharpe M; Simard S; Singer S; Stafford L; Stone J; Sultan S; Teixeira AL; Tiringer I; Turner A; Walker J; Walterfang M; Wang LJ; White J; Wong DK; Benedetti A; Thombs BD; | 31911325 LIBRARY |
| Title: | A Spike-Accum bioconjugate protein vaccine confers potent SARS-CoV-2-specific immunity | ||||
| Authors: | Pierre Bikorimana J, Caveney NA, El-Hachem N, Mandl GA, Capobianco JA, Stanga D, Abusarah J, Hancock MA, Farah R, Gonçalves MP, Falzarano D, Liao M, Hamonic G, Liu Q, Beaudoin S, Talbot S, Rafei M | ||||
| Link: | https://pubmed.ncbi.nlm.nih.gov/41054531/ | ||||
| DOI: | 10.1016/j.isci.2025.113314 | ||||
| Publication: | iScience | ||||
| Keywords: | Biological sciences; Immune response; Immunology; Natural sciences; | ||||
| PMID: | 41054531 | Category: | Date Added: | 2025-10-07 | |
| Dept Affiliation: |
CNSR
1 Department of Microbiology, Infectious Diseases, and Immunology, Université de Montréal, Montreal, QC H3T 1J4, Canada. 2 Centre for Blood Research, University of British Columbia, Vancouver, BC V6T 1Z3, Canada. 3 Department of Pharmacology and Toxicology, University of Toronto, Toronto, ON M5S 1A8, Canada. 4 Sainte-Justine Research Centre, Montreal, QC H3T 1C5, Canada. 5 Department of Chemistry and Biochemistry and Centre for NanoScience Research, Concordia University, Montreal, QC H3T 1J4, Canada. 6 Research and Development Branch, Defence Therapeutics Inc., Montreal, QC H4S 1Z9, Canada. 7 Department of Pharmacology and Physiology, Université de Montréal, Montreal, QC H3T 1J4, Canada. 8 SPR-MS Facility, Department of Pharmacology and Therapeutics, McGill University, Montreal, QC H3G 1Y6, Canada. 9 Vaccine and Infectious Disease Organization, University of Saskatchewan, Saskatoon, SK S7N 5E3, Canada. 10 Department of Biomedical & Molecular Sciences, Queen's University, Kingston, ON K7L 3J8, Canada. 11 Molecular Biology Program, Université de Montréal, Montreal, QC H3T 1J4, Canada. |
||||
Description: |
Despite the recent control of COVID-19, the devastating effects caused by the 3-year pandemic highlight the importance of developing effective vaccines to rapidly address future outbreaks. The present study describes a novel Spike (Sp) protein-based vaccine formulation using the Accum platform. Although Sp-Accum bioconjugation does not alter the overall protein structure, it triggers a substantial antibody titer: i) exhibiting higher specificity toward the S1 domain of Sp, ii) neutralizing Sp-ACE2 interactions, and iii) cross-reacting with various Sp variants. Besides validating the vaccine immunogenicity in rabbits, its administration in a "gold-standard" SARS-CoV-2 hamster model was shown to be safe while accelerating viral clearance without eliciting signs of pathological inflammation in the lungs of infected animals. Altogether, this proof-of-concept study not only demonstrates once again the versatility of the Accum technology in vaccine engineering, but it provides an enabling technology for the rapid development of value-added, protein-based vaccines for future pandemics. |
